Market: median 1d +0.0% · breadth 31.4% advancing across 188 names
Data as of — announcements 2026-08-07 · flow 2026-08-04 · prices 2026-08-06
New today: AR1, AVH, IVZ, KTA. New names versus yesterday's letter, so a continuing story doesn't read as fresh news.
Read these (4)
Today's announcements worth minutes, not seconds — triaged by deterministic rules (a raise, a result into live flow, quantified materiality). The LLM annotates; it never picks the bucket.
AR1 — QIC Invests $15 Million to Advance Rocklands Growth
AR1 secured $15M non-dilutive royalty financing from QIC to fund Stage 2 expansion scoping studies at Rocklands, underpinned by confirmed mine scheduling showing full 3.0 Mtpa utilisation until 2034. The deal indicators investor confidence in restart trajectory (Q3 2027) and positions Rocklands as a regional processing hub while preserving equity.
💰QIC Investment: $15 million · Royalty Structure: 0.80% on first 200kt Cu, then 0.30% · Processing Capacity (Current): 3.0 Mtpa · Stage 2 Target Capacity: 4.5–6.0 Mtpa
Materiality: Raise ~8.3% of $181m market cap; non-dilutive structure preserves free float; cash on hand ($71.6m) remains adequate for restart; royalty payable only post-production (post-Dec 2028 trigger).
Priced in? Stock +5% over 20d and +6% over 5d ahead of announcement; modest run-up suggests partial anticipation but incremental confidence from QIC's increased commitment and expansion timeline validation not fully reflected.
AVITA delivered solid sequential revenue growth (13% QoQ to $21.7m) with improving unit economics (gross margin 81.9%, operating expense leverage), narrowing net loss to $7.7m and reaffirming path to cash flow breakeven by Q4 2026. Capital discipline and high gross margins support the trajectory, though absolute revenue remains modest at ~$86–89m FY guidance against a $197m market cap.
Materiality: FY2026 revenue guidance of $86–89m represents ~45% of current market cap; Q2 net loss of $7.7m at current cash balance of $15.7m implies ~2 quarters' runway before breakeven, validating management's Q4 2026 target.
Priced in? Stock -4% over 20d, +1% over 5d; no significant run-up into results, suggesting modest pre-announcement positioning.
🌱 COILED · RSI 42 · 5d +0.8%confidence: high
high-confidence read, materiality quantified
IVZ — Musuma-1 Exploration Well Spud confirmed November 2026
Invictus has secured rig contract execution and confirmed November 2026 spud for Musuma-1, a high-impact exploration well targeting 1.2 Tcf gas and 73 MMbbl condensate outside the Mukuyu discovery. This represents material operational de-risking as the company transitions from rig procurement to active drilling execution.
Materiality: Musuma-1 is described as targeting one of the most significant undrilled exploration opportunities in the basin with potential to materially expand the resource base; quantified prospective resource (1.2 Tcf + 73 MMbbl) is substantial relative to $107m market cap, though heavily risk-weighted (unrisked, undiscovered accumulations).
Priced in? No run-up detected (0% in 5d, 0% in 20d); spud confirmation is new material information confirming operational timeline rather than anticipated news.
KTA · $11M — Strategic Placement to Fund Initial Zopkhito Earn-In
KTA is raising $2.4m at a 14% discount to close to fund its initial 10% stake in the Zopkhito antimony-gold project in Georgia, with a pathway to 80% ownership. The foreign resource (7.1Mt @ 3.7g/t Au, 225kt @ 11.6% Sb) is substantial but unJORC-compliant; maiden JORC estimate and preliminary mining studies are planned, positioning antimony as strategic upside alongside gold.
💰Placement size: $2.4m · Issue price: $0.006/share · Post-placement dilution: 400m new shares (~3.6x current if ~111m on issue) · Zopkhito gold resource (foreign): 7.1Mt @ 3.7g/t (815k oz Au)
Materiality: Raise ~22% of current $11m market cap; acquisition cost US$875k is modest relative to exploration spend; heavy dilution (400m shares issued) offsets capital efficiency of earn-in structure.
Priced in? Stock +27% over 20d and +17% over 5d into announcement; strong run-up suggests market anticipated capital raise and Zopkhito progress; result likely priced in.
Price-sensitive but routine — quarterlies and updates worth a headline-level pass.
LIN — Suspension from Quotation · price-sensitive — skim
Broker tape — caveats
Who bought and sold, by broker cohort, on a T+3 lag — spikes vs each stock's own baseline, multi-session streaks, and warnings where 'buying' is likely someone absorbing an exit.
⚠️ Exit / churn — bullish badge, bearish cause
LIN Flow spike (≥2.5× baseline) 3.5× — recent 'ceasing to be a substantial holder' notice